Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/BASILEA-PHARMACEUTICA-AG-130199/news/BASILEA-s-Antimykotikum-Isavuconazol-besteht-Zwischenanalyse-in-klinischer-Phase-III-Studie-13314706/?utm_source=whatsapp&utm_medium=social&utm_campaign=share